Aspargo Laboratories, Inc. is a clinical-stage biopharmaceutical company developing patient-focused solutions and must-have medicines by combining our innovative science and technologies and FDA’s 505(b)(2) approval pathway to enhance currently marketed drugs with well-known pharmacology profiles. Our company was formed for the purpose of commercializing innovative therapies qualifying for FDA approval under the section 505 b(2) regulatory approval pathway for new formulations of previously approved drugs. The company’s initial product candidate is a proprietary oral suspension spray formulation of sildenafil citrate, the active ingredient in VIAGRA®. Our mission is to develop patient-focused solutions and must-have medicines by applying our innovative science and technologies to enhance currently marketed drugs with well-known pharmacology profiles.